Drugs / NVSI-06-08
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05408312 | Jun 2022 → Feb 2024 | pneumonia | National Vaccine and Serum Institute, China | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05069129 | Oct 2021 → Dec 2023 | COVID-19 | National Vaccine and Serum Institute, China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVSI-06-08 | “Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm” NCT05408312 ↗ |
| Known as | Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) | “Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm” NCT05408312 ↗ |
| Modality | Vaccine | “NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine” PMID 35760812 ↗ Jun 2022 |
| Route | Intramuscular | “Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm” NCT05069129 ↗ |